Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Adler, David A.
Pajer, Kathy
Ellison, James M.
Dorwart, Robert
Siris, Samuel
Goldman, Howard
Lehman, Anthony
and
Berlant, Jeffrey
1995.
Clinical care update schizophrenia and the life cycle.
Community Mental Health Journal,
Vol. 31,
Issue. 3,
p.
249.
1995.
The drug treatment of patients with schizophrenia.
Drug and Therapeutics Bulletin,
Vol. 33,
Issue. 11,
p.
81.
Azorin, J‐M.
1995.
Long‐term treatment of mood disorders in schizophrenia.
Acta Psychiatrica Scandinavica,
Vol. 92,
Issue. s388,
p.
20.
Ramon, Shulamit
1996.
Mental Health in Europe.
p.
98.
Barnes, Thomas R. E.
McEvedy, Christopher J. B.
and
Nelson, Hazel E.
1996.
Management of Treatment Resistant Schizophrenia Unresponsive to Clozapine.
British Journal of Psychiatry,
Vol. 169,
Issue. S31,
p.
31.
Thakore, J. H.
Berti, C.
and
Dinan, T. G.
1996.
An open trial of adjunctive sertraline in the treatment of chronic schizophrenia.
Acta Psychiatrica Scandinavica,
Vol. 94,
Issue. 3,
p.
194.
Lavin, Michael R.
Siris, Samuel G.
and
Mason, Susan E.
1996.
What Is the Clinical Importance of Cigarette Smoking in Schizophrenia?.
The American Journal on Addictions,
Vol. 5,
Issue. 3,
p.
189.
EDGE, STACY C.
MARKOWITZ, JOHN S.
and
DEVANE, C. LINDSAY
1997.
Clozapine Drug-Drug Interactions: A Review of the Literature.
Human Psychopharmacology: Clinical and Experimental,
Vol. 12,
Issue. 1,
p.
5.
Sasson, Yehuda
Bermanzohn, Paul C.
and
Zohar, Joseph
1997.
Treatment of Obsessive-Compulsive Syndromes in Schizophrenia.
CNS Spectrums,
Vol. 2,
Issue. 4,
p.
34.
Mortimer, Ann
1997.
Treatment of the patient with long-term schizophrenia.
Advances in Psychiatric Treatment,
Vol. 3,
Issue. 6,
p.
339.
Zullino, Daniele
Bondolfi, Guido
and
Baumann, Pierre
1998.
The serotonin paradox: Negative symptoms and SSRI augmentation.
International Journal of Psychiatry in Clinical Practice,
Vol. 2,
Issue. 1,
p.
19.
Albus, M.
1998.
Therapie mit klassischen und neuen Neuroleptika.
p.
121.
Siris, Samuel G
2000.
Endogenous Stressors and Schizophrenic Heterogeneity.
Psychiatric Annals,
Vol. 30,
Issue. 10,
p.
645.
Silver, Henry
2001.
Fluvoxamine as an Adjunctive Agent in Schizophrenia.
CNS Drug Reviews,
Vol. 7,
Issue. 3,
p.
283.
Huppert, Jonathan D
Weiss, Kim A
Lim, Rosa
Pratt, Sarah
and
Smith, Thomas E
2001.
Quality of life in schizophrenia: contributions of anxiety and depression.
Schizophrenia Research,
Vol. 51,
Issue. 2-3,
p.
171.
HUPPERT, JONATHAN D.
and
SMITH, THOMAS E.
2001.
Longitudinal Analysis of Subjective Quality of Life in Schizophrenia: Anxiety as the Best Symptom Predictor.
The Journal of Nervous and Mental Disease,
Vol. 189,
Issue. 10,
p.
669.
Harris, Neil
2002.
Psychosocial Interventions for People with Schizophrenia.
p.
68.
Parepally, Haranath
Chakravorty, Sudeep
Levine, Joseph
Brar, Jaspreet S
Patel, Amit M
Baird, James W
Chalasani, Lokaranjit
Delaney, Joyce A
Atzert, Rebecca
and
Chengappa, K.N.Roy
2002.
The use of concomitant medications in psychiatric inpatients treated with either olanzapine or other antipsychotic agents.
Progress in Neuro-Psychopharmacology and Biological Psychiatry,
Vol. 26,
Issue. 3,
p.
437.
Emsley, R.A.
and
Stein, D.J.
2002.
Anxiety Disorders.
p.
163.
Hiemke, Christoph
Peled, Avi
Jabarin, Mahmoud
Hadjez, Jack
Weigmann, Harald
HÄrtter, Sebastian
Modai, Ilan
Ritsner, Michael
and
Silver, Henry
2002.
Fluvoxamine Augmentation of Olanzapine in Chronic Schizophrenia: Pharmacokinetic Interactions and Clinical Effects.
Journal of Clinical Psychopharmacology,
Vol. 22,
Issue. 5,
p.
502.
eLetters
No eLetters have been published for this article.